License and supply agreement with Genuine Health
RNS & Investor News
OptiBiotix Capital Reorganisation
28 February 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the "Capital Reduction") in order to create distributable reserves to allow the Company to make future dividend payments.
OptiBiotix is pleased to announce that, following shareholder approval which was granted on 25 January 2018, the High Court of Justice made an order confirming the Capital Reduction on 27 February 2018.
Following the registration of the Court order confirming the Capital Reduction by the Registrar of Companies in England and Wales, the Capital Reduction became effective 27 February 2018.
Stephen O'Hara, CEO of OptiBiotix, commented: "I am pleased to report that both shareholders and the Courts have confirmed the capital reduction. This allows OptiBiotix to make future dividend or 'dividend in specie' distributions to the Company's shareholders should it be appropriate to do so. This is part of OptiBiotix's strategy of building value across its divisions and where possible releasing value back to shareholders."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
Liam Murray / Jo Turner
|Tel: 020 7213 0880|
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
|Tel: 020 7220 0500|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020